Report Type: Therapy Reports
Report Category: Other Diseases
Report Subcategory: Uterine Leiomyoma or Uterine Fibroids
Price: $ 2999.00
Date: January 2022

Uterine Leiomyoma or Uterine Fibroids: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Uterine Leiomyoma or Uterine Fibroids
Uterine Leiomyoma or Uterine Fibroids is a non-cancerous growths in the uterus that can develop during a woman's childbearing years. Symptoms include heavy menstrual bleeding, prolonged periods and pelvic pain.

Top 10 Companies:
Pfizer Inc
Bayer AG
Novartis AG
AbbVie Inc
Abbott Laboratories
Takeda Pharmaceutical Co Ltd
AstraZeneca Plc
Teva Pharmaceutical Industries Ltd
Astellas Pharma Inc
Neurocrine Biosciences Inc